Epigral Limited — PPTs, 27-07-2026: Investor Presentation

Epigral delivered a solid Q1 FY27. Revenue grew 15% YoY to ₹709 Cr, driven by a 5% sales volume increase and improved realization, despite macroeconomic challenges. Plant utilization remained above 80%.

The company is strategically expanding its high-value specialty chemicals portfolio. New projects include an Epoxy Resin & Formulations plant (125 KTPA by H2 FY28) and a Multi-Purpose Plant (MPP) for Epichlorohydrin and Chlorotoluene value chains (H2 FY28). These expansions leverage internal raw materials, strengthening the integrated complex.

Capacity enhancements for CPVC Resin (additional 75 KTPA) and Epichlorohydrin (additional 50 KTPA) are on track for Q2 FY27 commissioning, alongside a new Wind Solar Hybrid Power Plant. Pilot plants for Epoxy Resin and MPP are also being set up.

Financially, EBITDA rose 10% YoY to ₹179 Cr (25% margin), and Profit After Tax (PAT) surged 25% YoY to ₹99 Cr (14% margin). EPS was ₹23.0. Net Debt/EBITDA stood at 0.8x.

Management maintains a positive outlook, anticipating growth from India's economy and stabilizing conditions. They are committed to diversifying the portfolio, aiming for 70% revenue from derivatives & specialty segments by FY28.